Highly specific targeting of human acute myeloid leukaemia cells using pharmacologically active nanoconjugates by Yasinska, Inna M. et al.
Nanoscale
COMMUNICATION
Cite this: Nanoscale, 2018, 10, 5827
Received 19th December 2017,
Accepted 2nd February 2018
DOI: 10.1039/c7nr09436a
rsc.li/nanoscale
Highly speciﬁc targeting of human acute myeloid
leukaemia cells using pharmacologically active
nanoconjugates†
Inna M. Yasinska,*a Giacomo Ceccone,b Isaac Ojea-Jimenez,b Jessica Ponti,b
Rohanah Hussain,c Giuliano Siligardi,c Steﬀen M. Berger,d Elizaveta Fasler-Kan,d
Marco Bardelli,e Luca Varani,e Walter Fiedler,f Jasmin Wellbrock,f Ulrike Raap,g
Bernhard F. Gibbs,*a,g Luigi Calzolai*b and Vadim V. Sumbayev*a
In this study we used 5 nm gold nanoparticles as delivery platforms
to target cancer cells expressing the immune receptor Tim-3 using
single chain antibodies. Gold surfaces were also covered with the
cytotoxic drug rapamycin which was immobilised using a gluta-
thione linker. These nanoconjugates allowed highly speciﬁc and
eﬃcient delivery of cytotoxic rapamycin into human malignant
blood cells.
Introduction
Highly specific targeting of human malignant blood cells with
the purpose of delivering cytotoxic drugs into them is a very
promising but not a well-developed strategy for leukaemia
treatment. Leukaemia is a blood/bone marrow cancer originat-
ing from self-renewing malignant immature precursors or
transformed leukocytes. It is a severe and often fatal systemic
malignancy which aﬀects haematopoiesis, immune defence
and followed by many other body systems.1 Chemotherapy of
leukaemia is often problematic since the drugs used are gener-
ally toxic and could kill other growing and quickly proliferating
cells such as stem cells, thus aﬀecting normal haematopoiesis
and consequent recovery.2 Therefore, the use of drug delivery
systems selectively targeting leukaemia cells could reduce
overall toxicity and would be a considerable advantage in anti-
leukaemia therapy.
We have recently shown that citrate-stabilised gold nano-
particles (AuNPs) can be used as drug delivery platforms.3,4
They display a reasonable level of biocompatibility, anti-
inflammatory properties and inability to aﬀect cells on their
own.3,5 In this study we designed a fundamentally novel type
of nanocomplex, where 5 nm AuNPs were used as a delivery
platform and carried a 27 kDa single chain antibody against T
cell immunoglobulin and mucin domain 3 (Tim-3) at a ratio of
1 AuNP : 1 antibody molecule. The rest of the gold surface was
covered with rapamycin immobilised in the form of gluta-
thione-SH ester.
The immune receptor Tim-3 is highly expressed in human
acute myeloid leukaemia (AML) cells compared to healthy
leukocytes and thus can be used as a receptor for targeted
drug-delivery complexes.6–8 Rapamycin inhibits the activity of
a mammalian target of rapamycin (mTOR), an enzyme display-
ing serine/threonine protein kinase activity which acts as a
master regulator of translational pathways in AML cells.
Inhibiting mTOR leads to rapid killing of AML cells.3,8 Using
these nanoconjugates (NCJ) we managed to successfully
deliver rapamycin into AML cells and reduce mTOR activity.
The concentration of rapamycin required to reach such an
eﬀect was at least 50 times lower compared to that of free rapa-
mycin required to achieve a similar eﬀect. We therefore con-
cluded that our technology is of potential use for highly
specific targeting of AML cells.
Materials and methods
Materials
RPMI-1640 medium, foetal bovine serum and supplements
and basic laboratory chemicals were purchased from Sigma
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(Suﬀolk, UK). Maxisorp™ microtitre plates were provided
either by Nunc (Roskilde, Denmark) or Oxley Hughes Ltd
(London, UK). Antibodies against phospho-S65 and total
eIF4E-BP were obtained from Cell Signaling Technology
(Danvers, MA USA). Goat anti-mouse and goat anti-rabbit fluo-
rescence dye-labelled antibodies were obtained from Li-Cor
(Lincoln, Nebraska USA). The anti-Tim-3 mouse monoclonal
antibody and its single chain variant were produced as pre-
viously described.9 All other chemicals purchased were of the
highest grade of purity and available commercially from Fisher
Scientific (Loughborough, UK) and Sigma (Suﬀolk, UK).
Gold nanoparticles
The synthesis of 5 nm AuNPs was performed essentially as
described previously.10 Briefly, 5 ml of aqueous gold(III) chlo-
ride trihydrate (10 mM) and 2.5 ml of aqueous sodium citrate
(100 mM) were added to 95 ml of MilliQ-water in a round
bottom flask equipped with a magnetic stirrer, and the result-
ing pale yellow solution was allowed to cool down to 1–2 °C.
Under vigorous stirring 1 ml of chilled (4 °C) aqueous sodium
borohydride (0.1 M) was added and the resulting dark red
solution was then stirred for further 10 min in an ice bath
before being allowed to warm to the room temperature.
Nanomaterials were characterised as described before.3
Cells
THP-1 human leukaemia monocytic macrophages were pur-
chased from the European collection of Cell Cultures
(Salisbury, UK). They were grown in RPMI 1640 media sup-
plemented with 10% foetal calf serum, penicillin (50 IU ml−1)
and streptomycin sulphate (50 µg ml−1) and used for the
experiments during passages 8–20.
Primary human AML cells were obtained from the sample
bank of the University Medical Centre Hamburg-Eppendorf
(Ethik-Kommission der Ärztekammer Hamburg, reference:
PV3469). The cells were cultured in IMDM medium containing
15% BIT 9500 serum substitute, 100 µM mercaptoethanol, 100
ng ml−1 stem cell factor (SCF), 50 ng ml−1 FLT3 ligand, 20
ng ml−1 G-CSF, 20 ng ml−1 IL-3, 1 µM UM729 and 500 nM
stemregenin 1 (SR1) as described before.11
Western blot analysis
Phosphorylation of the mTOR substrate – eukaryotic initiation
factor 4E binding protein (eIF4E-BP) in the position Serine 65
(S65) was analysed by western blot analysis as described pre-
viously.8 Actin expressions were measured in order to validate
equal protein loading. Li-Cor (Lincoln, Nebraska USA) goat sec-
ondary antibodies conjugated with fluorescent dyes for 60 min
were employed according to the manufacturer’s protocol and
proteins were visualised using a Li-Cor Odyssey imaging
system. The western blot data were subjected to quantitative
analysis using Odyssey software determining the levels of
mTOR-dependent phosphorylation of eIF4e-BP.8
Characterisation of the presence of a cell surface of Tim-3 and
its natural ligand/traﬃcking partner galectin-9
Cell surface expression of Tim-3 and its natural ligand galec-
tin-9 were analysed using fluorescence-activated cell sorting
(FACS) as previously described.12 Briefly, THP-1 cells were
incubated with PMA to increase the expression of the
Tim-3/Gal-9 complex or left untreated. The cells were then
fixed with freshly prepared 2% paraformaldehyde, washed 3×
with PBS, and permeabilised with 0.1% TX-100. In a control
set of experiments the THP-1 cells were not fixed/permeabi-
lized. All the cells were stained with fluorochrome-labelled
antibodies for 1 hour at room temperature and analysed using
a FACS Calibur cytometer with CellQuestPro software (Becton
Dickinson, USA). We also performed a Li-Cor on cell assay
(also known as in cell assay, ICA) in order to stain cell surface-
based Tim-3. In cell western (ICW) analysis using methanol as
a cell permeabilisation agent was employed to monitor diﬀer-
ences between Tim-3 localised inside and outside the cell.
Both assays were described previously.8
Synchrotron radiation circular dichroism spectroscopy
Nanomaterials were characterised at the B23 beamline for syn-
chrotron radiation circular dichroism (SRCD), Diamond Light
Source (Didcot, UK). SRCD measurements were performed
using a 10 cm path length cell, 3 mm aperture diameter and
800 µl capacity using Module B with a 1 nm increment, 1 s
integration time, and 1.2 nm bandwidth at 23 °C.13,14 The
results obtained were processed using the CDApps
programme13–15 and Origin software (OriginLab™).
Transmission electron microscopy (TEM) and dynamic light
scattering (DLS)
The NCJ suspension (3 µl) was manually spotted, after 2 min
of sonication, on pre-treated (glow discharge, LEICA EM
ACE200, 10 mA–30 s) Formvar Carbon coated 200 mesh copper
grids (Agar Scientific, USA). Samples were then dried overnight
in a desiccator. Transmission electron microscopy (TEM-JEOL
JEM 2100, JEOL-Italy) coupled with energy dispersive X-ray
spectroscopy (EDX; X-Flash Detector 5030, Brüker-Italy) was
used for imaging and elemental analysis at 120 kV.
Quantitative analysis was obtained by the Cliﬀ–Lorimer model
using QUANTAX 200 software (Brüker, Italy). The results were
expressed as mass% of the whole sample measured in the ana-
lysed image and compared with NCJ precursors.
The average size in the solution of the nanoconjugate was
also assessed by DLS (Zetasizer Nano Zs, Malvern Instruments;
Malvern, UK).16
Statistical analysis
Each experiment was performed at least three times and stat-
istical analysis when comparing two events at a time was con-
ducted using a two-tailed Student’s t-test. Statistical probabil-
ities (p) were expressed as *, where p < 0.05, **p < 0.01 and
***p < 0.001.
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Results and discussion
Generation and characterisation of nanoconjugates
The anti-Tim-3 single-chain antibody (anti-Tim-3-ScAb) was
coupled to 5 nm AuNPs using glutathione (GSH, tripeptide
containing γ-glutamate, cysteine-SH and glycine) as a linker. A
0.05 M solution of GSH was incubated for 2 h at room tem-
perature with a 1 : 1 mixture of water solutions of 0.4 M
1-ethyl-3-(3-dimethylpropyl)-carbodiimide (EDC) and 0.1 M
N-hydroxysuccinimide (NHS) to allow the activation of –COOH
groups of the GSH thus enabling them to interact with the
amino groups of the anti-Tim-3-ScAb. Activated GSH was then
mixed with anti-Tim-3-ScAb in an equimolar ratio and incu-
bated for at least 2 h at 37 °C. The antibody was then mixed
with 5 nm AuNPs (0.5 mM) at a ratio of 1 AuNP : 1 antibody
molecule. This mixture was incubated for at least 18 h at room
temperature.
The available amount of AuNPs was calculated using the
following formula:
NAuNP ¼ mtotal Au=mAuNP ðm ¼ mass; N ¼ quantityÞ; ð1Þ
mtotal Au ¼ CAu ðmol l1Þ MWAu ðg mol1Þ  VAuNP ðlÞ
(C = molar concentration, MW = molecular weight, VAuNP = the
volume of the AuNP suspension used);
m1 AuNP ¼ ρAu  V1 AuNP; ð2Þ
(ρ = density, V = volume; ρAu = 19.3 g cm
−3);
V1 AuNP ¼ 4=3 πR 3; ðR ¼ radius of a AuNPÞ ð3Þ
R ¼ d1 AuNP=2; ðd ¼ diameter of 1 AuNP expressed in cmÞ:
ð4Þ
The amount of antibody molecules was calculated from the
molar weight of the anti-Tim-3-ScAb (27 000 g mol−1) and the
Avogadro constant so that 1 mole of anti-Tim-3-ScAb contained
6.02 × 1023 antibody molecules.
Following antibody immobilisation, the remaining gold
surface of each particle was covered with molecules of rapamy-
cin esterified with the GSH ester prepared as previously
described4 so that 1 AuNP carried a maximum of 1000 rapamy-
cin molecules. The size of AuNPs (5 nm) was confirmed using
DLS. The size of the NCJ was approximately 10.8 nm.
Materials were characterised using SRCD spectroscopy
measuring both near-UV and far-UV spectra. HGS-CO-anti-
Tim-3-ScAb and HSG-CO-rapamycin (HGS-CO is the gluta-
thione residue), or a mixture of both, AuNPs carrying either
anti-Tim-3-ScAb alone or rapamycin were characterised as con-
trols (Fig. 1). We found that both near-UV and far-UV NCJ (NCJ
is the same as that represented in Fig. 5 and 7 containing rapa-
mycin and anti-Tim-3-ScAb [1000 : 1] per nanoparticle) dis-
played spectral profiles that were diﬀerent from those of the
controls suggesting that the generation of the complexes was
successful with diﬀerent conformational behaviours (Fig. 2).
Characterisation of nanoparticle construct conformations
In the far-UV region (190–250 nm), the SRCD spectrum of the
single chain antibody-GSH (ScAb-GSH) showed a negative
band at 230 nm and a positive band at 205 nm (Fig. 2, black)
indicating significant β-strand conformation. In particular, the
smaller intensity of the positive band was indicative of the
presence of two types of handedness of the β-strand backbone
conformation of the single chains. Here, a small excess of the
Fig. 1 Nanoconjugates used for the characterisation of biological tests.
Six types of materials were generated: (A) glutathione GSH-activated
anti-Tim-3-ScAb, (B) glutathione GSH activated rapamycin, (C) a mixture
of A and B at a ratio of 1 : 1000, (D) 5 nm AuNPs carrying anti-Tim-3-
ScAb, (E) 5 nm AuNPs carrying rapamycin and (F) nanoconjugate con-
taining 5 nm AuNPs coupled with anti-Tim-3-ScAb and 1000 rapamycin
via GSH.
Fig. 2 Observed far-UV SRCD spectra of ScAb-GSH (black), ScAb-
GSH-NP (green), nanoconjugate NCJ (rapamycin-GSH and ScAb-GSH
covalently attached to Au nanoparticles [1000 : 1 : 1]) (yellow), rapamy-
cin-GSH (red), rapamycin-GSH-NP (magenta), a mixture of rapamycin-
GSH with ScAb-GSH (blue), the calculated spectrum of the mixture of
rapamycin-GSH and ScAb-GSH (dashed blue) simulated by adding the
spectrum of rapamycin-GSH (red) to that of ScAb-GSH (black) and cal-
culated NCJ (dashed yellow) simulated by adding the spectrum of ScAb-
GSH-NP (green) to that of rapamycin-GSH-NP (magenta). Each
observed spectrum was the average of 4 consecutive repeated scans.
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right-handed twist was observed, which is characterised by the
bisignate shape with a negative band in the 215–230 nm
region and a positive band in the 195–205 nm region. This
interpretation appears to be consistent with the β-strand con-
formation content estimation of about 45%, of which 18% was
left-handed and 27% right-handed using the BestSel algor-
ithm.16 The single chain antibody-GSH covalently attached to a
gold nanoparticle (ScAb-GSH-NP, Fig. 2, green) retained the
β-strand type of SRCD spectrum observed without the gold
nanoparticle but with a slight reduction of the left-handed
β-strand content.
The stability of the nanoconjugates was tested by incubat-
ing the materials at increasing temperatures and pH levels.
This was followed by spectrophotometric detection of reduced
glutathione using 5,5′-dithiobis-(2-nitrobenzoic acid)17 and
antibody detection using western blotting (to see if these com-
ponents were displaced from the gold surface). We did not
observe detectable amounts of either GSH (data not shown) or
antibody under any of the conditions tested (ESI Fig. 1†).
We also used TEM to characterise the nanoconjugates. We
observed that NCJ particles show spherical morphology typical
of AuNPs with a primary size diameter (with a short axis
length of 5.85 nm). Lower electron-dense zones, compared to
gold, were both around single particles and aggregates/
agglomerates (indicated by arrows in ESI Fig. 2†) could be due
to AuNP-bound antibodies. EDX analysis shows that the per-
centage of sulfur is practically negligible in the AuNP alone
(0.89%), while it increases (as expected) in the AuNP–Ab
complex (2.28%) and in the NCJ sample (5.54%). These results
fit qualitatively well with expected outcomes. In fact, both the
anti-Tim-3 antibody and rapamycin were coupled to AuNPs
using glutathione that contains a cysteine amino acid with an
–SH terminal group. Overall, the data show that both the anti-
body and rapamycin are bound to AuNPs (ESI Fig. 3†).
The DLS data for the NCJ sample give a Z-average of around
2 µm and a polydispersity index of 0.39. These results indicate
that in solution the sample is polydispersed. As shown pre-
viously18 in DLS the presence of a few agglomerates could
cover the signal of smaller particles present in solution. This
interpretation is consistent with the TEM results (ESI Fig. 1†)
which show the presence of a large number of small AuNP
conjugates together with the presence of larger agglomerates.
It has been reported that several antibody molecules can be
successfully immobilised on a single particle.19 In our case, a
one to one ratio was optimal to ensure that there was suﬃcient
space on the AuNP surface to be covered with rapamycin.
The SRCD spectrum of rapamycin-GSH showed qualitatively
a β-strand type of shape (Fig. 2, red), a negative CD band at
about 225 nm and a positive band at about 205 nm. This may
reflect the conformation of the cysteinyl-glycine dipeptide
chromophore, which was too small in terms of intensity to be
analysed with BestSel accurately. Upon attachment to the gold
nanoparticle (NP), rapamycin-GSH-NP (Fig. 2 magenta)
revealed a significant spectral change showing only a positive
band at 215 nm with the disappearance of the negative band
at 225 nm. These SRCD changes appear to be dominated by
the π–π* transitions of the amide bonds though the contri-
bution from the trienyl group sensitive to the conformational
changes of the flexible rapamycin skeleton backbone which
cannot be ruled out.
It is interesting to note that the SRCD spectrum of the
mixture of rapamycin-GSH and ScAb-GSH [(Rap-GSH) + (ScAb-
GSH), Fig. 2, blue] was not superimposable to that calculated
by adding the spectrum of rapamycin-GSH to the one of ScAb-
GSH (Calc. [(Rap-GSH) + (ScAb-GSH)], Fig. 2, dashed blue),
suggesting binding interactions between rapamycin-GSH and
ScAb-GSH. Similarly, the SRCD changes between the observed
spectrum of the NCJ (Fig. 2, yellow) and the one calculated by
adding the spectrum of rapamycin-GSH-NP to that of ScAb-
GSH-NP (Calc-NCJ-NP, Fig. 2, dashed yellow) highlighted
another conformational behaviour of the ScAb-GSH and rapa-
mycin-GSH when coupled to the same nanoparticle. As for
rapamycin-GSH with and without coupling to the gold nano-
particle, the BestSel secondary structure content estimation of
the mixture [(Rapa-GSH) + (ScAb-GSH)] and NCJ from SRCD
spectra were not suﬃciently accurate to be considered.
The characterisation by SRCD spectroscopy of the samples
and in particular NCJ that appear to be active against primary
leukaemia cells is also important for quality control since the
SRCD spectra can be used as a fingerprint of these constructs.
Undiﬀerentiated and diﬀerentiated THP-1 human AML cells
have diﬀerent amounts of surface-based Tim-3
THP-1 human myeloid leukaemia cells express Tim-3 which
acts as a receptor and a traﬃcker for galectin-9, a protein
which protects AML cells against host immune defence.6,20
Using FACS (Fig. 3) we found that undiﬀerentiated THP-1 cells
have much less surface-based Tim-3 and galectin-9, respect-
ively, than the cells exposed for 24 h to 100 nM phorbol
12-myristate 13-acetate (PMA). In undiﬀerentiated cells,
surface-based Tim-3 molecules are occupied with galectin-9
and can only be clearly detected using on cell assay where the
cells were pre-incubated with the anti-Tim-3 antibody for 2 h
that enables the displacement of galectin-9 (Fig. 4). PMA acti-
vates protein kinase C alpha (PKCα), an enzyme that triggers
the exocytosis of Tim-3 and the secretion of galectin-9, thus
increasing the amount of both proteins on the cell surface.
However, both undiﬀerentiated and diﬀerentiated THP-1 cells
express high amounts of Tim-3 and most of these proteins
were observed to translocate onto the cell surface upon the
stimulation of the cells with PMA as detected by the on
cell assay and in cell western analysis (Fig. 4). Some of the
Tim-3 molecules were bound to galectin-9, others were present
in their free form and thus became clearly detectable by
both FACS and the on cell assay/in cell western analysis (Fig. 3
and 4).
We exposed the resting undiﬀerentiated THP-1 cells for 2 h
at 37 °C to 100 ng ml−1 human stem cell factor (SCF) that trig-
gers mTOR activation and causes a non-significant increase in
the level of cell surface-based Tim-3 in THP-1 cells. Exposures
were performed with and without 1 h pre-treatment with NCJ
(allowing for a maximal possible concentration of rapamycin
Communication Nanoscale
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of 200 nM – given the ideal case when each AuNP coupled with
anti-Tim-3-ScAb carries a maximum of 1000 rapamycin mole-
cules (illustrated in Fig. 5)). We found that nanoconjugates
were able to abrogate SCF-induced mTOR-dependent eIF4E-BP
phosphorylation but did not impact on background S65-
phospho-eIF4E-BP levels (Fig. 6). Neither of the treatments
aﬀected cell viability.
We then asked whether an increase in Tim-3 on the cell
surface would lead to a greater mTOR-inhibiting eﬀect of the
nanoconjugates. THP-1 cells were exposed to 100 nM PMA for
24 h followed by 3 h exposure to the nanoconjugates (illus-
trated in Fig. 7). The same conditions as described above were
applied. In this case NCJ completely abrogated the mTOR-
dependent phosphorylation of eIF4E-BP (Fig. 8). Neither of the
treatments aﬀected cell viability. Interestingly, AuNPs carrying
Fig. 3 Surface-based and total (intracellular + surface-based) Tim-3
and its ligand galectin-9 (carried by Tim-3) in THP-1 cells. Non-treated
THP-1 cells (left two panels) and those treated for 24 h with 100 nM
PMA (right two panels) were subjected to the measurement of surface-
based and total (cells were permeabilised using methanol) Tim-3 and
galectin-9 by FACS as described in the Materials and methods section.
Each experiment was performed at least three times. Images are from
one experiment representative of three which gave similar results.
Fig. 4 Tim-3 is mostly located inside resting THP-1 cells but is externa-
lised after PMA-dependent PKCα activation. Tim-3 was measured using
a Li-Cor on cell assay with (in cell western) or without (on cell assay)
methanol permeabilisation (see the Materials and methods section).
Exposure to the anti-Tim-3 antibody was performed for 2 h. Images are
from one experiment representative of ﬁve which gave similar results.
Data show mean values ± SEM of ﬁve independent experiments;
**p < 0.01.
Fig. 5 Schematic representation of rapamycin delivery into a resting
THP-1 human AML cell. The scheme shows SCF-induced activation of
the mTOR pathway (in particular, mTOR-catalysed phosphorylation of
the eIF4E-BP). It also demonstrates the delivery path of rapamycin and
inhibition of mTOR kinase activity.
Fig. 6 Nanoconjugates prevent but do not abolish mTOR activity in
undiﬀerentiated THP-1 cells. Cells were pre-treated with NCJ for 1 h to
allow for the delivery of maximally 200 nM of rapamycin in the medium.
Cells were then exposed for 2 h to 100 ng ml−1 of SCF or left without
further treatment followed by the measurement of phospho-S65 and
total eIF4E-BP by western blot as described in the Materials and
methods section. Images are from one experiment representative of
three which gave similar results. Data show mean values ± SEM of three
independent experiments; *p < 0.05.
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either anti-Tim-3-ScAb or rapamycin did not aﬀect mTOR
activity in either resting or PMA-treated THP-1 cells (data not
shown).
Based on these results one could suggest that the successful
inhibition of the mTOR-dependent phosphorylation of
eIF4E-BP in THP-1 human AML cells depends on the amount
of Tim-3 on the cell surface. Anti-Tim-3-ScAb molecules
coupled with AuNPs interacted with THP-1 cells, which alike a
vast majority of blood cells can perform endocytosis. GSH was
then cleaved by membrane-associated enzymes releasing rapa-
mycin inside the target cell (otherwise, the eﬀect will not be
observed, since only free rapamycin is capable of inhibiting
mTOR activity inside AML cells).
It is important to note that in order to achieve a complete
abrogation of mTOR activity in THP-1 cells, the concentration
of free rapamycin has to be at least 10 µM. The use of NCJ led
to the same eﬀect but at the rapamycin concentration 50 times
lower than the one needed when using the drug in its free
form.
The results obtained were validated using primary human
AML cells. Tim-3 was clearly expressed on the cell surface as
detected by the on cell assay vs. in cell western analysis. The
cells appeared to be highly sensitive to the eﬀects of nanocon-
jugates since the levels of phospho-S65-eIF4E-BP were signifi-
cantly downregulated after 3 h of exposure to NCJs. Almost
complete attenuation was observed after 24 h of exposure
(Fig. 9).
Conclusions
Our results demonstrate that the targeted nanocarrier we have
developed enables the delivery of otherwise toxic drugs into
leukaemia cells with a high level of eﬃciency through Tim-3.
Successful delivery depends on the cell surface expression of
the target protein, which in our case was Tim-3. These nano-
conjugates now require further studies using ex vivo and
in vivo systems. This technology might also be considered for
highly specific capturing of target cells that carry a surface-
based protein biomarker of interest.
Conﬂicts of interest
There are no conflicts of interest to declare.
Fig. 7 Schematic representation of rapamycin delivery into a PMA-
diﬀerentiated THP-1 human AML cell. The scheme shows PMA-induced
activation of the mTOR pathway in a PKCα-dependent manner. It also
demonstrates the delivery path of rapamycin and the subsequent inhi-
bition of the mTOR kinase activity.
Fig. 8 Nanoconjugates attenuate mTOR activity in PMA-diﬀerentiated
THP-1 cells. Cells were exposed for 24 h to 100 nM PMA followed by 3 h
of exposure to nanoconjugates. Images are from one experiment repre-
sentative of four which gave similar results. Data show mean values ±
SEM of four independent experiments; **p < 0.01.
Fig. 9 Nanoconjugates attenuate mTOR activity in primary human AML
cells. Tim-3 expression was mostly conﬁned to the cell surface as
measured by the in-cell assay and in-cell western analysis (A). Cells were
exposed for 3 (B) or 24 (C) h to nanoconjugates followed by western
blot analysis of S65 phosphorylation of eIF4E-BP. Images are from one
experiment representative of four which gave similar results. Data show
mean values ± SEM of four independent experiments; **p < 0.01.
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